EcoDrugPlus

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSBMUG00000020745
Gene Symbol: FGFR3
1 Cross references
196 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSBMUG00000007195
Gene Symbol: FGFR4
3 Cross references
122 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSBMUG00000023081
Gene Symbol: FLT1
3 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSBMUG00000023185
Gene Symbol: FLT3
3 Cross references
134 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSBMUG00000011679
Gene Symbol: FLT4
3 Cross references
198 Possible Orthologues:

Folate Hydrolase 1

Ensembl ID : ENSBMUG00000018980
Gene Symbol: FOLH1
1 Cross references
211 Possible Orthologues:

Follicle-Stimulating Hormone Receptor

Ensembl ID : ENSBMUG00000011570
Gene Symbol: LOC102285011
3 Cross references
200 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSBMUG00000016509
Gene Symbol: FFAR2
3 Cross references
339 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSBMUG00000004546
Gene Symbol: FRK
3 Cross references
217 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSBMUG00000011487
Gene Symbol: GLA
3 Cross references
197 Possible Orthologues:

Galectin 1

Ensembl ID : ENSBMUG00000009672
Gene Symbol: LGALS1
3 Cross references
330 Possible Orthologues:

Galectin 3

Ensembl ID : ENSBMUG00000009866
Gene Symbol: LGALS3
3 Cross references
218 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).